A 40-year-old male presented with cervical lymphadenopathy
Presented by
DR. Sharmin Easmin
Phase- B Resident
Green Unit
Department of Haematology
BSMMU
Particulars of the patient�
Presenting complaints
History of present illness
Cont….
Cont…..
General Examination
Cont…..
Systemic Examination
Salient feature:
Mr.Jewel,40years,old,Imam, normotensive, nondiabetic, nonsmoker, hailing from Noakhali presented with nodular swelling over the right side of the neck for one and half month. These swelling are insidious on onset, painless and gradually increasing in size. There is no history of fever, night sweat, weight loss, cough, SOB, haemoptysis, H/O bleeding, skin rash, arthritis contact with TB patient or history of exposure. No swelling other side of the body. His bowel and bladder habits are normal. There is no family history of such illness. He has no drug or treatment history.
On examination-
General examination:
Appearance: Normal, Body build : Average, Decubitus: On choice, No Anaemia, jaundice, clubbing, cyanosis, koilonychia, leukonychia or oedema. Pulse: 88 beat/min, BP: 120/80 mm of Hg, Temperature: 98oF,Respiratory: 22/min.
CBC
| |
Hb | 12.1 gm/dl |
Total WBC count | 3.6 x 10 u/L |
Platelet count | 110 x 10 u/L |
ESR | 03 mm Hg/1st hour |
Other parameter:
| |
LDH | 190 mg/dl |
Creatinine | 1.2 mg/dl |
Electrolytes | Na 136 mmol/L, K 3.9 mmol/L |
SGPT | 45 IU/ml |
Bilirubin | 0.9 mg/dl |
Albumin | 38 mg/dl |
Mantoux test | Negative |
Lymph node histopathology
Microscopic examination:
Section show lymph node, nodal architecture is lost and replaced by lymphocytes, plasma cells, histocytes and eosinophils.
Few Reed-Sternberg like cells is also seen.
Diagnosis:
Lymphoproliferative disorder, features are highly suggestive of Hodgkin lymphoma
Immunohistochemistry:
Confirm Diagnosis:
Hodgkin Lymphoma
(mixed cellularity)
FDG PET Scan shows
Diagnosis:
Prognostic factors for early stage HL
* Rajkumar et el 2022, Hoffbrand 8th edition
NCCN guideline version 2.2020
Advanced stage (IIB-IV)
Standard & escalated BEACOPP vs. COPP alter with ABVD
MOPP, ABVD & MOPP alternating with ABVD
The Stanford V vs. ABVD
6 cycle ABVD vs. 4 cycle esc BEACOPP + 2 cycle std BEACOPP
6 cycle BEACOPP + RT to PET positive site
6 x esc BEACOPP + RT to PET positive site
2 cycle ABVD>> PET scan
Patients with negative scan>
4 cycle ABVD/ AVD
Pt with positive scan>
4 x BEACOPP-14/ 3 x escalated BEACOPP>
PET>
Negative> 2 x BEACOPP
Positive> switch off
early HDCT+ASCT as early intensification
Brentuximab + AVD
Brentuximab + ABVD
Brentuximab + BrECAPP
Brentuximab + BrECADD
PD- 1 Ab +AVD
PD- 1 Ab + Brentuximab
Ann Arbor Staging
Stage I | Involvement of a single LN region or lymphoid structure |
Stage II | Involvement of two or more LN regions or LN structures on the same side of the diaphragm |
Stage III | Involvement of LN regions or lymphoid structures on both sides of the diaphragm |
Stage IV | Diffuse or disseminated involvement of one or more extralymphatic organs or tissues with or without associated LN enlargement Involvement of liver and bone marrow always considered stage IV |